TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
11/30/23 16:05 | 11/28/23 | JSPR | Jasper Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Wiggans Thomas G | CA | D | P | 6 | 0.6486 | 0 | 10 | 25 | 50 | D | |||||||||||||||
11/22/23 16:06 | 11/21/23 | JSPR | Jasper Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Wiggans Thomas G | CA | D | P | 6 | 0.6383 | 0 | 10 | 33 | 40 | D | |||||||||||||||
11/20/23 20:14 | 11/16/23 | JSPR | Jasper Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Wiggans Thomas G | CA | D | P.m | 18 | 0.6080 | 0 | 30 | New | 30 | D | |||||||||||||||
12/7/22 16:29 | 12/5/22 | PRDS | Pardes Biosciences, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Wiggans Thomas G | CA | DO | CEO | P | 14 | 1.09 | 0 | 13 | 33 | 50 | D | ||||||||||||||
12/5/22 16:21 | 12/1/22 | PRDS | Pardes Biosciences, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Wiggans Thomas G | CA | DO | CEO | P.m | 39 | 1.05 | 0 | 38 | New | 38 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |